Inhibiting c-Abl has shown promising therapeutic effects in iPSC derived motor neurons from ALS patients with SOD1 mutations, TDP-43 mutations, or sporadic ALS, as well as in a SOD1G93A transgenic ALS mouse model [150, 151]. Here, TARDBP is linked to amyotrophic lateral sclerosis.